Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monofer vs Oral Iron Sulphate in NDD-CKD with Iron Deficiency Anemia
NCT01102413Phase 3Completed
- Sponsor
- Pharmacosmos
- Start
- Apr 2010
- Primary completion
- Jun 2014
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Pharmacosmos. Primary endpoint: Change in Hemoglobin Concentration From Baseline to Week 4. Started Apr 2010; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT01102413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01102413.